What is the clinical significance of premature atrial contractions (PACs) observed on an electrocardiogram (ECG) in an otherwise healthy adult?

Clinical Significance of PACs on ECG

In an otherwise healthy adult, premature atrial contractions (PACs) on ECG are not benign—they represent a significant marker of future atrial fibrillation, stroke, and mortality risk that warrants risk stratification and monitoring, even in the absence of structural heart disease.

Risk Stratification Based on PAC Burden

The clinical significance depends critically on PAC frequency:

High-Risk PAC Patterns (Require Active Management)

• Frequent PACs on 24-48 hour Holter monitoring are associated with:
  • 3-fold increased risk of atrial fibrillation (HR 2.96) 1
  • 2.5-fold increased risk of stroke (HR 2.54) 1
  • 2-fold increased risk of all-cause mortality (HR 2.14) 1
  • Increased cardiovascular death (HR 2.89) and coronary artery disease mortality (HR 2.74) 2

These associations persist even after adjusting for confounding factors 2, suggesting PACs are not merely markers but potentially causative through the atrial cardiomyopathy pathway 3.

The Atrial Cardiomyopathy Concept

PACs should be viewed as a signaling marker of underlying atrial cardiomyopathy, where structural, functional, and biochemical atrial changes lead to both arrhythmias and thromboembolic events 3. This explains why PAC-associated stroke risk exists independently of documented AF occurrence 4—AF may be an epiphenomenon rather than the sole causal pathway 3.

Diagnostic Approach

Initial Assessment

When PACs are detected on standard 12-lead ECG:

1. Obtain 24-48 hour Holter monitoring to quantify PAC burden 5

   • This is essential because single PACs on 12-lead ECG have insufficient evidence for risk prediction 1
   • Frequent PACs are defined by elevated counts over 24 hours

2. Assess for structural heart disease with echocardiography 5

   • Even in "structurally normal" hearts, look for subtle atrial abnormalities
   • Left atrial enlargement (diameter index ≥3 cm/m²) suggests atrial cardiopathy 6

3. Screen for AF with extended monitoring if PAC burden is high 3

   • Consider implantable loop recorders or wearable devices
   • The 2024 ESC guidelines require ECG documentation of ≥30 seconds for AF diagnosis 7

Management Algorithm

For Frequent PACs (High Burden on Holter):

Monitoring Strategy:

• Serial Holter monitoring to track PAC burden over time 5
• Extended cardiac monitoring for AF detection 3
• Consider NT-proBNP and P-wave terminal force in V1 as additional atrial cardiopathy markers 6

Treatment Considerations:

• Antiarrhythmic therapy may be warranted when:

  • PACs cause significant symptoms affecting quality of life 5
  • PAC-induced cardiomyopathy develops 5
  • Very high PAC burden (specific thresholds remain undefined) 3

• Anticoagulation remains controversial 3

  • Current evidence does not support routine anticoagulation for PACs alone without documented AF
  • The ARCADIA trial showed no benefit of apixaban over aspirin in cryptogenic stroke patients with atrial cardiopathy markers including PACs 6
  • However, this remains an area of active investigation 3

For Infrequent/Isolated PACs:

• Reassurance if truly asymptomatic
• Baseline echocardiogram to confirm structural normality
• Consider repeat Holter in 6-12 months if any risk factors present
• Patient education about AF symptoms

Critical Caveats

Common Pitfalls to Avoid:

1. Don't dismiss PACs as benign without quantifying burden—the paradigm has shifted from "benign finding" to "risk marker" 5, 3
2. Don't rely solely on 12-lead ECG—extended monitoring is necessary for risk stratification 1
3. Don't assume AF is the only mechanism linking PACs to stroke—atrial cardiomyopathy provides an independent pathway 3, 4

Age Considerations:

• The evidence base primarily involves older adults (mean age 52-76 years) 1
• Younger patients with truly isolated PACs and no risk factors may have more benign prognosis, though prospective data are limited 5

Evidence Gaps and Future Directions

Current limitations include 3:

• No consensus definition of "excessive" PAC burden requiring intervention
• Lack of prospective trials on antiarrhythmic therapy efficacy
• Unclear role of anticoagulation in high PAC burden without documented AF
• Need for molecular targets and biomarkers to identify highest-risk patients

The key clinical message: PACs in "normal hearts" are not normal—they signal increased cardiovascular risk requiring systematic evaluation and longitudinal monitoring, with treatment decisions based on PAC burden, symptoms, and evidence of atrial cardiomyopathy.